ClinicalTrials.gg
RecruitingNCT06388811Updated Feb 19, 2025

Validity and Reliability Study of the Turkish Version of the Early Osteoarthritis Questionnaire

An observational study in Early Knee Osteoarthritis, sponsored by Istanbul University. Recruiting at 1 site in Turkey. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-19.

Sponsored by Istanbul University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as recruiting.
  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
220
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Osteoarthritis, Knee by Istanbul University — 3 open to participants now, 3 under way, none of them phase 3. Osteoarthritis, Knee · Istanbul University.

Started
2025
with 1 other
Observational
2 of 11
1 open now
Registered
9th of 11
by date

Among the 11 studies in Osteoarthritis, Knee by Istanbul University, this one is one of 2 that started in 2025, is one of 2 observational ones, and was the 9th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

3 of the 11 studies in Osteoarthritis, Knee by Istanbul University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Osteoarthritis, Knee by Istanbul University, or all of them as a file.
02

Study summary

The symptoms of early osteoarthritis (OA) are quite similar to established knee OA, they differ, particularly in frequency, intensity, and severity. For this reason, in 2023, the International Symposium of intra-articular treatment (ISIAT) technical experts panel (TEP-technical experts panel) published for the first time a questionnaire designed to assess and monitor the follow-up and clinical progression of patients affected by early knee OA. Early management of knee OA is recommended by various guidelines because this approach may alter the course and clinical features of the disease, especially when considering disease-modifying agents that may delay disease progression.

Therefore, the assessment of early knee OA with a questionnaire may facilitate the follow-up of OA in the early stages of the disease when treatment is likely to be more effective. This approach will allow to reduce disability and improve patients' quality of life. While creating the Early Osteoarthritis Questionnaire (EOAQ), it was aimed to have a complete, short and easy-to-understand questionnaire and to ensure that the respondents could complete the questionnaire easily and in a short time. The EOAQ consists of 11 questions. The questions were divided into two different groups. While the first two questions were related with clinical characteristics, the other nine questions aimed to investigate the results reported by the patient. For each question, there are three responses depending on the number of episodes: Never, rarely (between one and three episodes) and frequently (more than three episodes) within a 6-month period. Turkish validity and reliability study of the EOAQ has not been conducted yet.

For the translation of the questionnaire, the guide recommended by Beaton et al. for the cultural adaptation of questionnaires will be used. According to this guideline the original EOAQ will be translated into Turkish by two experts independently of each other, and then a single Turkish version will be created by two experts working together. This Turkish version will then be translated back into English by an expert who can speak both languages at an advanced level. The experts will then evaluate the translation and adapt the questionnaire accordingly. After the completion of the translated form, 110 patients and 110 control group participants who applied to Istanbul University Istanbul Faculty of Medicine, Department of Physical Medicine and Rehabilitation and met the inclusion criteria will be included. The participants will be informed verbally and in writing about the purpose, duration and method of the study and will be asked to sign an "Informed Voluntary Consent Form" after their consent is obtained. Participants will fill in the Turkish version of the questionnaire. Along with the questionnaire, knee pain will be questioned with the Numeric Rating Scale (0=no pain, 10=the most severe pain you experience) and disability will be questioned with the WOMAC Questionnaire, whose Turkish validity and reliability study has been conducted. Test-retest method will be applied for reliability analyses; therefore, at least 30 patients among the patients included in the study will complete the questionnaire twice (the second evaluation will be 2 weeks after the first evaluation).

03

Conditions studied

  • Early Knee Osteoarthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Patients with early knee osteoarthritis and population without knee pain for control gorup

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-

For the patient group :

  1. Meeting the diagnostic criteria for early symptomatic knee OA

    • In the absence of risk factors, two mandatory symptoms (pain when climbing up and down stairs and increased pain with overload) are present
    • In the presence of 1 or 2 risk factors, at least pain when climbing up and down stairs is present among the two mandatory symptoms
    • Presence of at least 1 mandatory symptom in the presence of 3 or more risk factors
  2. Over 40 years of age
  3. Signing the form
  4. Being able to read and write Turkish
  5. To be able to come to the follow-ups required by the study

For the control group:

  1. Absence of knee pain
  2. Over 40 years of age
  3. Signing the informed consent form
  4. Being able to read and write Turkish
  5. To be able to come to the follow-ups required by the study

Exclusion criteria

Exclusion Criteria:

  • For the patient group:

    1. Active inflammatory arthritis
    2. The presence of widespread pain
    3. Being under 40 years of age
    4. Having stage 1-4 knee OA according to Kellgren and Lawrence
    5. Recent trauma or injury
    6. Symptom duration of more than 6 months
    7. Having a mental capacity, cognition level that prevents understanding and completing the questionnaire

For the control group:

  1. Having knee pain
  2. Being under 40 years of age
  3. Having a mental capacity, cognition level that prevents understanding and completing the questionnaire
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
220 participants (estimated)
Patient registry
No

Groups and cohorts

  • Early Knee Osteoarthritis Patients

    Other: Early Osteoarthritis Questionnaire

  • Population Without Knee Pain

    Other: Early Osteoarthritis Questionnaire

Interventions

  • OtherEarly Osteoarthritis Questionnaire

    Self administered questionnaire

06

What researchers measure

Primary outcomes

  1. Numeric Rating Scale

    Patients rate their level of pain between 0-10 during movement, rest and night, 0 indicates no pain, 10 indicates the worst imaginable pain

    Time frame: Baseline, second week

  2. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)

    WOMAC consists of 24 items consisting of 3 subgroups that the patients answer themselves. These subgroups include; pain intensity during various positions or movements, severity of joint stiffness and difficulty in performing daily functional activities. It has 3 forms: 5-point Likert, 100 mm visual analogue scale and 11-box numerical evaluation scale. The 5 point likert form will be filled in this study. Higher scores indicate worse pain, stiffness, or physical function.

    Time frame: Baseline, second week

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Mar 2025, 1 month after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2024
First posted
Apr 29, 2024
StartActual
Feb 19, 2025
Primary completionEst.
Mar 19, 2025
CompletionEst.
Mar 19, 2025
Last update
Feb 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06388811
Responsible party
Fatma Merih Akpınar (Assistant Professor, Istanbul University) — Principal investigator
First posted
Apr 29, 2024
Start date
Feb 19, 2025
Primary completion
Mar 19, 2025 (estimated)
Completion
Mar 19, 2025 (estimated)
Last update
Feb 19, 2025

Study contacts

Fatma Merih Akpınar
Contact
merihcaliskan@gmail.com
+905333558843

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion